ロード中...

Gilteritinib: A Novel FLT3 Inhibitor for Relapsed/Refractory Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is the most common adult leukemia, with an overall poor prognosis. New agents targeting various receptors may improve treatment outcomes and overall survival. FMS-like tyrosine kinase 3 (FLT3) is a targetable mutation occurring in one third of AML patients. It contribute...

詳細記述

保存先:
書誌詳細
出版年:J Adv Pract Oncol
主要な著者: Marjoncu, Dennis, Andrick, Benjamin
フォーマット: Artigo
言語:Inglês
出版事項: Harborside Press LLC 2020
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7517771/
https://ncbi.nlm.nih.gov/pubmed/33542854
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.6004/jadpro.2020.11.1.7
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!